Ayala Pharmaceuticals, Inc. (AYLA)


0.00 (0.00%)
Symbol AYLA
Price $0.5339
Beta 0.000
Volume Avg. 0.05M
Market Cap -
Shares () -
52 Week Range 0.3568-5.9425
1y Target Est -
DCF Unlevered AYLA DCF ->
DCF Levered AYLA LDCF ->
ROE -308.79% Strong Sell
ROA -829.80% Strong Sell
Operating Margin -
Debt / Equity -159.33% Sell
P/E -
P/B -7.51 Strong Sell


Consensus EPS

Upgrades & Downgrades

Latest AYLA news

Dr. Roni Mamluk M.D., Ph.D.
NASDAQ Global Market

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.